UNSPSC 51285701: Betamipron

This classification denotes an artificial sweetener with the molecular formula C10H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3W0M245736, chemically known as beta-alanine, n-benzoyl- but more generally known as betamipron, which bears US NIH Compound Identifier 71651. European Medicines Agency schedules Betamipron in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05800MIG. The term BETAMIPRON is an International Non-Proprietary Name.

UNSPSC 51285701 Betamipron, a Commodity code, appears in state and local procurement with minimal direct relevance to the nominal product. The recent opportunities tagged to this code show state and local governments buying naloxone and drug deactivation systems, generic pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, medical and first aid supplies for emergency response, and market intelligence on direct-to-manufacturer prescription programs — none of which align with betamipron, a pharmaceutical agent for specific clinical use. The mismatch suggests either systematic miscoding or that the code itself does not map cleanly to current state and local procurement practice. Issuing bodies in the recent record include a county health department (Seminole County, Florida), a state health commission (Texas HHS Commission), a city fire and rescue department (City of Tampa), and a multistate cooperative purchasing alliance (Minnesota MMCAP, serving multiple states including Oregon).

Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon, with the multistate cooperative model expanding reach across participating jurisdictions. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's sheltered-market IFB for medical and first aid supplies with an estimated contract value of $700,000 and a response deadline of March 13, 2026, and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. The Texas HHS Commission also issued an RFI in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs. The code shows little relevant recent activity directly tied to betamipron procurement.